Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals

While mRNA vaccines against SARS-CoV-2 are exceedingly effective in preventing symptomatic infection, their immune response features remain to be clarified. In the present prospective study, 225 healthy individuals in Japan, who received two BNT162b2 doses, were enrolled. Correlates of BNT162b2-elic...

Full description

Saved in:
Bibliographic Details
Published inScientific reports Vol. 11; no. 1; pp. 22848 - 10
Main Authors Maeda, Kenji, Amano, Masayuki, Uemura, Yukari, Tsuchiya, Kiyoto, Matsushima, Tomoko, Noda, Kenta, Shimizu, Yosuke, Fujiwara, Asuka, Takamatsu, Yuki, Ichikawa, Yasuko, Nishimura, Hidehiro, Kinoshita, Mari, Matsumoto, Shota, Gatanaga, Hiroyuki, Yoshimura, Kazuhisa, Oka, Shin-ichi, Mikami, Ayako, Sugiura, Wataru, Sato, Toshiyuki, Yoshida, Tomokazu, Shimada, Shinya, Mitsuya, Hiroaki
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 24.11.2021
Nature Publishing Group
Nature Portfolio
Subjects
631/250/255/2514
631/326/590/2293
631/326/596/4130
Adult
Aged
Antibodies, Neutralizing - blood
Antibodies, Neutralizing - immunology
Antibodies, Neutralizing - pharmacology
Antibodies, Viral - blood
Antibodies, Viral - immunology
Antibody response
BNT162 Vaccine - adverse effects
BNT162 Vaccine - pharmacokinetics
COVID-19
COVID-19 - blood
COVID-19 - immunology
COVID-19 Vaccines - adverse effects
COVID-19 Vaccines - pharmacokinetics
Drug-Related Side Effects and Adverse Reactions
Female
Humanities and Social Sciences
Humans
Immune response
Immunogenicity, Vaccine - immunology
Immunoglobulin G
Immunologic Tests
Japan
Kinetics
Male
Middle Aged
mRNA
multidisciplinary
Neutralization
Prospective Studies
SARS-CoV-2 - genetics
SARS-CoV-2 - immunology
SARS-CoV-2 - pathogenicity
Science
Science (multidisciplinary)
Severe acute respiratory syndrome coronavirus 2
Side effects
Vaccines
Virions
Japan
Online AccessGet full text

Cover

Abstract While mRNA vaccines against SARS-CoV-2 are exceedingly effective in preventing symptomatic infection, their immune response features remain to be clarified. In the present prospective study, 225 healthy individuals in Japan, who received two BNT162b2 doses, were enrolled. Correlates of BNT162b2-elicited SARS-CoV-2-neutralizing activity (50% neutralization titer: NT 50 ; assessed using infectious virions) with various determinants were examined and the potency of sera against variants of concerns was determined. Significant rise in NT 50 s was seen in sera on day 28 post-1st dose. A moderate inverse correlation was seen between NT 50 s and ages, but no correlation seen between NT 50 s and adverse effects. NT 50 s and SARS-CoV-2-S1-binding-IgG levels on day 28 post-1st dose and pain scores following the 2nd dose were greater in women than in men. The average half-life of NT 50 s was ~ 68 days, and 23.6% (49 out of 208 individuals) failed to show detectable neutralizing activity on day 150. While sera from elite-responders (NT 50 s > 1,500: the top 4% among the participants) potently to moderately blocked all variants of concerns examined, some sera with low NT 50 s failed to block the B.1.351-beta strain. Since BNT162b2-elicited immunity against SARS-CoV-2 is short, an additional vaccine or other protective measures are needed.
AbstractList While mRNA vaccines against SARS-CoV-2 are exceedingly effective in preventing symptomatic infection, their immune response features remain to be clarified. In the present prospective study, 225 healthy individuals in Japan, who received two BNT162b2 doses, were enrolled. Correlates of BNT162b2-elicited SARS-CoV-2-neutralizing activity (50% neutralization titer: NT 50 ; assessed using infectious virions) with various determinants were examined and the potency of sera against variants of concerns was determined. Significant rise in NT 50 s was seen in sera on day 28 post-1st dose. A moderate inverse correlation was seen between NT 50 s and ages, but no correlation seen between NT 50 s and adverse effects. NT 50 s and SARS-CoV-2-S1-binding-IgG levels on day 28 post-1st dose and pain scores following the 2nd dose were greater in women than in men. The average half-life of NT 50 s was ~ 68 days, and 23.6% (49 out of 208 individuals) failed to show detectable neutralizing activity on day 150. While sera from elite-responders (NT 50 s > 1,500: the top 4% among the participants) potently to moderately blocked all variants of concerns examined, some sera with low NT 50 s failed to block the B.1.351-beta strain. Since BNT162b2-elicited immunity against SARS-CoV-2 is short, an additional vaccine or other protective measures are needed.
While mRNA vaccines against SARS-CoV-2 are exceedingly effective in preventing symptomatic infection, their immune response features remain to be clarified. In the present prospective study, 225 healthy individuals in Japan, who received two BNT162b2 doses, were enrolled. Correlates of BNT162b2-elicited SARS-CoV-2-neutralizing activity (50% neutralization titer: NT ; assessed using infectious virions) with various determinants were examined and the potency of sera against variants of concerns was determined. Significant rise in NT s was seen in sera on day 28 post-1st dose. A moderate inverse correlation was seen between NT s and ages, but no correlation seen between NT s and adverse effects. NT s and SARS-CoV-2-S1-binding-IgG levels on day 28 post-1st dose and pain scores following the 2nd dose were greater in women than in men. The average half-life of NT s was ~ 68 days, and 23.6% (49 out of 208 individuals) failed to show detectable neutralizing activity on day 150. While sera from elite-responders (NT s > 1,500: the top 4% among the participants) potently to moderately blocked all variants of concerns examined, some sera with low NT s failed to block the B.1.351-beta strain. Since BNT162b2-elicited immunity against SARS-CoV-2 is short, an additional vaccine or other protective measures are needed.
Abstract While mRNA vaccines against SARS-CoV-2 are exceedingly effective in preventing symptomatic infection, their immune response features remain to be clarified. In the present prospective study, 225 healthy individuals in Japan, who received two BNT162b2 doses, were enrolled. Correlates of BNT162b2-elicited SARS-CoV-2-neutralizing activity (50% neutralization titer: NT50; assessed using infectious virions) with various determinants were examined and the potency of sera against variants of concerns was determined. Significant rise in NT50s was seen in sera on day 28 post-1st dose. A moderate inverse correlation was seen between NT50s and ages, but no correlation seen between NT50s and adverse effects. NT50s and SARS-CoV-2-S1-binding-IgG levels on day 28 post-1st dose and pain scores following the 2nd dose were greater in women than in men. The average half-life of NT50s was ~ 68 days, and 23.6% (49 out of 208 individuals) failed to show detectable neutralizing activity on day 150. While sera from elite-responders (NT50s > 1,500: the top 4% among the participants) potently to moderately blocked all variants of concerns examined, some sera with low NT50s failed to block the B.1.351-beta strain. Since BNT162b2-elicited immunity against SARS-CoV-2 is short, an additional vaccine or other protective measures are needed.
While mRNA vaccines against SARS-CoV-2 are exceedingly effective in preventing symptomatic infection, their immune response features remain to be clarified. In the present prospective study, 225 healthy individuals in Japan, who received two BNT162b2 doses, were enrolled. Correlates of BNT162b2-elicited SARS-CoV-2-neutralizing activity (50% neutralization titer: NT50; assessed using infectious virions) with various determinants were examined and the potency of sera against variants of concerns was determined. Significant rise in NT50s was seen in sera on day 28 post-1st dose. A moderate inverse correlation was seen between NT50s and ages, but no correlation seen between NT50s and adverse effects. NT50s and SARS-CoV-2-S1-binding-IgG levels on day 28 post-1st dose and pain scores following the 2nd dose were greater in women than in men. The average half-life of NT50s was ~ 68 days, and 23.6% (49 out of 208 individuals) failed to show detectable neutralizing activity on day 150. While sera from elite-responders (NT50s > 1,500: the top 4% among the participants) potently to moderately blocked all variants of concerns examined, some sera with low NT50s failed to block the B.1.351-beta strain. Since BNT162b2-elicited immunity against SARS-CoV-2 is short, an additional vaccine or other protective measures are needed.
While mRNA vaccines against SARS-CoV-2 are exceedingly effective in preventing symptomatic infection, their immune response features remain to be clarified. In the present prospective study, 225 healthy individuals in Japan, who received two BNT162b2 doses, were enrolled. Correlates of BNT162b2-elicited SARS-CoV-2-neutralizing activity (50% neutralization titer: NT50; assessed using infectious virions) with various determinants were examined and the potency of sera against variants of concerns was determined. Significant rise in NT50s was seen in sera on day 28 post-1st dose. A moderate inverse correlation was seen between NT50s and ages, but no correlation seen between NT50s and adverse effects. NT50s and SARS-CoV-2-S1-binding-IgG levels on day 28 post-1st dose and pain scores following the 2nd dose were greater in women than in men. The average half-life of NT50s was ~ 68 days, and 23.6% (49 out of 208 individuals) failed to show detectable neutralizing activity on day 150. While sera from elite-responders (NT50s > 1,500: the top 4% among the participants) potently to moderately blocked all variants of concerns examined, some sera with low NT50s failed to block the B.1.351-beta strain. Since BNT162b2-elicited immunity against SARS-CoV-2 is short, an additional vaccine or other protective measures are needed.While mRNA vaccines against SARS-CoV-2 are exceedingly effective in preventing symptomatic infection, their immune response features remain to be clarified. In the present prospective study, 225 healthy individuals in Japan, who received two BNT162b2 doses, were enrolled. Correlates of BNT162b2-elicited SARS-CoV-2-neutralizing activity (50% neutralization titer: NT50; assessed using infectious virions) with various determinants were examined and the potency of sera against variants of concerns was determined. Significant rise in NT50s was seen in sera on day 28 post-1st dose. A moderate inverse correlation was seen between NT50s and ages, but no correlation seen between NT50s and adverse effects. NT50s and SARS-CoV-2-S1-binding-IgG levels on day 28 post-1st dose and pain scores following the 2nd dose were greater in women than in men. The average half-life of NT50s was ~ 68 days, and 23.6% (49 out of 208 individuals) failed to show detectable neutralizing activity on day 150. While sera from elite-responders (NT50s > 1,500: the top 4% among the participants) potently to moderately blocked all variants of concerns examined, some sera with low NT50s failed to block the B.1.351-beta strain. Since BNT162b2-elicited immunity against SARS-CoV-2 is short, an additional vaccine or other protective measures are needed.
ArticleNumber 22848
Author Fujiwara, Asuka
Mikami, Ayako
Yoshida, Tomokazu
Maeda, Kenji
Mitsuya, Hiroaki
Shimizu, Yosuke
Matsumoto, Shota
Gatanaga, Hiroyuki
Oka, Shin-ichi
Tsuchiya, Kiyoto
Sugiura, Wataru
Matsushima, Tomoko
Ichikawa, Yasuko
Shimada, Shinya
Takamatsu, Yuki
Kinoshita, Mari
Uemura, Yukari
Yoshimura, Kazuhisa
Amano, Masayuki
Nishimura, Hidehiro
Sato, Toshiyuki
Noda, Kenta
Author_xml – sequence: 1
  givenname: Kenji
  surname: Maeda
  fullname: Maeda, Kenji
  email: kmaeda@ri.ncgm.go.jp
  organization: Department of Refractory Viral Infections, National Center for Global Health and Medicine (NCGM) Research Institute
– sequence: 2
  givenname: Masayuki
  surname: Amano
  fullname: Amano, Masayuki
  organization: Department of Clinical Sciences, Kumamoto University Hospital
– sequence: 3
  givenname: Yukari
  surname: Uemura
  fullname: Uemura, Yukari
  organization: Center of Clinical Sciences, NCGM
– sequence: 4
  givenname: Kiyoto
  surname: Tsuchiya
  fullname: Tsuchiya, Kiyoto
  organization: AIDS Clinical Center, NCGM
– sequence: 5
  givenname: Tomoko
  surname: Matsushima
  fullname: Matsushima, Tomoko
  organization: Sysmex Corporation
– sequence: 6
  givenname: Kenta
  surname: Noda
  fullname: Noda, Kenta
  organization: Sysmex Corporation
– sequence: 7
  givenname: Yosuke
  surname: Shimizu
  fullname: Shimizu, Yosuke
  organization: Center of Clinical Sciences, NCGM
– sequence: 8
  givenname: Asuka
  surname: Fujiwara
  fullname: Fujiwara, Asuka
  organization: Department of Refractory Viral Infections, National Center for Global Health and Medicine (NCGM) Research Institute
– sequence: 9
  givenname: Yuki
  surname: Takamatsu
  fullname: Takamatsu, Yuki
  organization: Department of Refractory Viral Infections, National Center for Global Health and Medicine (NCGM) Research Institute
– sequence: 10
  givenname: Yasuko
  surname: Ichikawa
  fullname: Ichikawa, Yasuko
  organization: JCHO Kumamoto General Hospital
– sequence: 11
  givenname: Hidehiro
  surname: Nishimura
  fullname: Nishimura, Hidehiro
  organization: JCHO Kumamoto General Hospital
– sequence: 12
  givenname: Mari
  surname: Kinoshita
  fullname: Kinoshita, Mari
  organization: JCHO Kumamoto General Hospital
– sequence: 13
  givenname: Shota
  surname: Matsumoto
  fullname: Matsumoto, Shota
  organization: JCHO Kumamoto General Hospital
– sequence: 14
  givenname: Hiroyuki
  surname: Gatanaga
  fullname: Gatanaga, Hiroyuki
  organization: AIDS Clinical Center, NCGM
– sequence: 15
  givenname: Kazuhisa
  surname: Yoshimura
  fullname: Yoshimura, Kazuhisa
  organization: Tokyo Metropolitan Institute for Public Health
– sequence: 16
  givenname: Shin-ichi
  surname: Oka
  fullname: Oka, Shin-ichi
  organization: AIDS Clinical Center, NCGM
– sequence: 17
  givenname: Ayako
  surname: Mikami
  fullname: Mikami, Ayako
  organization: Center of Clinical Sciences, NCGM
– sequence: 18
  givenname: Wataru
  surname: Sugiura
  fullname: Sugiura, Wataru
  organization: Center of Clinical Sciences, NCGM
– sequence: 19
  givenname: Toshiyuki
  surname: Sato
  fullname: Sato, Toshiyuki
  organization: Sysmex Corporation
– sequence: 20
  givenname: Tomokazu
  surname: Yoshida
  fullname: Yoshida, Tomokazu
  organization: Sysmex Corporation
– sequence: 21
  givenname: Shinya
  surname: Shimada
  fullname: Shimada, Shinya
  organization: JCHO Kumamoto General Hospital
– sequence: 22
  givenname: Hiroaki
  surname: Mitsuya
  fullname: Mitsuya, Hiroaki
  email: hmitsuya@hosp.ncgm.go.jp
  organization: Department of Refractory Viral Infections, National Center for Global Health and Medicine (NCGM) Research Institute, Department of Clinical Sciences, Kumamoto University Hospital, Experimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34819514$$D View this record in MEDLINE/PubMed
BookMark eNp9Uk1v1DAQjVARLUv_AAcUiQsXU48_sskFqaz4qFSBxBauluNMtl4Se2sni5YfwW_G25TS9lBfxh6_9-Z5PM-zA-cdZtlLoG-B8vIkCpBVSSgDQqHilOyeZEeMCkkYZ-zgzv4wO45xTdOSrBJQPcsOuSihkiCOsj8LHwJ2esCY-zZ3OA5Bd_a3dauT5em3JVn4H4SRJZDauiZlc-0GW_tmlweMG-8i5r_scJnrZoshHbBt0QwxwZrc9v3oMP9pHQ7WxNy6_P2XCyhYzchWG2NdqptgSXhrm1F38UX2tE0Bj2_iLPv-8cPF4jM5__rpbHF6ToyQckdk2UgBTJRz02ioaolU4JxWtQHZtFWLICSgrg3lrSnmrGCSU1oIXhRznprFZ9nZpNt4vVabYHsddsprq64TPqyUDslzh0q3hhojaLJdCg5VCcBo0fKUa7DSPGm9m7Q2Y91jY9DtW3hP9P6Ns5dq5beqLICzZGqWvbkRCP5qxDio3kaDXacd-jEqVtAEo8D2tV4_gK79GFxq1R4Fcw6T4Ku7jm6t_Pv2BGATwAQfY8D2FgJU7cdLTeOl0nip6_FSu0QqH5CMHfRg_f5VtnucyidqTHXcCsN_24-w_gLiI-QW
CitedBy_id crossref_primary_10_1126_scitranslmed_adn0396
crossref_primary_10_1016_j_heliyon_2024_e24513
crossref_primary_10_3390_v16020292
crossref_primary_10_3390_idr15010003
crossref_primary_10_1038_s41591_022_01721_6
crossref_primary_10_1016_j_jinf_2024_106179
crossref_primary_10_1080_21645515_2023_2193074
crossref_primary_10_1093_infdis_jiac393
crossref_primary_10_1038_s41598_023_28591_3
crossref_primary_10_1186_s12879_023_08272_2
crossref_primary_10_3390_vaccines12070742
crossref_primary_10_1016_j_anai_2022_10_003
crossref_primary_10_1016_j_vaccine_2022_04_043
crossref_primary_10_1038_s41598_022_17071_9
crossref_primary_10_1016_j_jinf_2023_01_038
crossref_primary_10_1016_j_jiac_2022_08_026
crossref_primary_10_1093_cid_ciab1048
crossref_primary_10_1093_infdis_jiac209
crossref_primary_10_1016_j_jiac_2022_03_002
crossref_primary_10_1038_s41598_022_19537_2
crossref_primary_10_3390_vaccines9090990
crossref_primary_10_7883_yoken_JJID_2022_093
crossref_primary_10_1016_j_ijid_2023_01_023
crossref_primary_10_3390_medicina58020309
crossref_primary_10_3390_vaccines10030451
crossref_primary_10_1016_j_eclinm_2024_102720
crossref_primary_10_1016_j_jiac_2022_09_012
crossref_primary_10_1038_s41598_023_44484_x
crossref_primary_10_1016_j_ijid_2023_11_004
crossref_primary_10_3390_vaccines11010120
crossref_primary_10_1016_j_cmi_2022_07_002
crossref_primary_10_1016_j_jinf_2023_08_012
crossref_primary_10_3390_vaccines10050640
crossref_primary_10_1016_j_ijid_2022_04_058
crossref_primary_10_1038_s41598_022_19581_y
crossref_primary_10_1080_13102818_2024_2432986
crossref_primary_10_3390_vaccines12050516
crossref_primary_10_1128_spectrum_02716_22
crossref_primary_10_3390_vaccines10081312
crossref_primary_10_1016_j_ypmed_2022_107123
crossref_primary_10_1016_j_ijid_2022_03_017
crossref_primary_10_1128_spectrum_01315_22
crossref_primary_10_3389_fimmu_2023_1217206
crossref_primary_10_1016_j_jinf_2022_05_016
crossref_primary_10_3390_v15061276
crossref_primary_10_1371_journal_pone_0283658
crossref_primary_10_3390_vaccines10030439
crossref_primary_10_1016_j_virusres_2024_199520
crossref_primary_10_1016_j_jiac_2022_04_018
Cites_doi 10.1016/S0140-6736(21)00432-3
10.1016/S0140-6736(20)32661-1
10.1097/QAD.0b013e3280b0774a
10.1056/NEJMoa2027906
10.1016/S1473-3099(21)00263-2
10.1001/jama.2020.16656
10.1056/NEJMoa2035389
10.1038/s41586-021-03738-2
10.1056/NEJMoa2034577
10.1016/S2213-2600(20)30079-5
10.1038/s41586-021-03777-9
10.1038/s41586-021-03471-w
10.1056/NEJMc2103916
10.1016/j.cell.2020.06.043
10.1038/s41586-020-2008-3
10.1056/NEJMoa2101544
10.1016/S0140-6736(20)30211-7
10.1056/NEJMoa2103055
10.1038/s41598-021-84733-5
10.1016/0304-3959(87)91074-8
10.1056/NEJMoa2107659
10.1073/pnas.2002589117
10.1038/s41586-020-2521-4
10.1101/2021.03.17.20200246
10.1073/pnas.2018975117
10.35772/ghm.2021.01010
10.1038/s41598-021-84387-3
10.1038/s41586-021-03841-4
10.1101/2021.03.09.21252641
10.35772/ghm.2020.01040
10.1126/science.370.6518.748
10.1016/S0140-6736(21)01290-3
10.1038/s41591-021-01270-4
10.1101/2021.06.29.450453
10.1038/s41586-020-2012-7
10.1128/mBio.01833-20
10.1016/S0140-6736(21)02183-8
ContentType Journal Article
Copyright The Author(s) 2021
2021. The Author(s).
The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2021
– notice: 2021. The Author(s).
– notice: The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88A
88E
88I
8FE
8FH
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
COVID
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M1P
M2P
M7P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOA
DOI 10.1038/s41598-021-01930-y
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Biology Database (Alumni Edition)
Medical Database (Alumni Edition)
Science Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
Coronavirus Research Database
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
ProQuest Health & Medical Collection
Medical Database
Science Database
Biological Science Database
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Biology Journals (Alumni Edition)
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Science Journals
ProQuest One Academic Eastern Edition
Coronavirus Research Database
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE

Publicly Available Content Database
CrossRef

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 5
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2045-2322
EndPage 10
ExternalDocumentID oai_doaj_org_article_afc0cc4016284319811206f3cc4de9a3
PMC8613264
34819514
10_1038_s41598_021_01930_y
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations Japan
GeographicLocations_xml – name: Japan
GrantInformation_xml – fundername: National Institutes of Health
– fundername: Japan Agency for Medical Research and Development
  grantid: JP20fk0108160; JP20fk0108502
  funderid: http://dx.doi.org/10.13039/100009619
– fundername: Ministry of Health, Labor and Welfare, Japan
  grantid: JPMH20HA1006
– fundername: Japan Agency for Medical Research and Development
  grantid: JP20fk0108502
– fundername: Japan Agency for Medical Research and Development
  grantid: JP20fk0108160
– fundername: ;
– fundername: ;
  grantid: JP20fk0108160; JP20fk0108502
– fundername: ;
  grantid: JPMH20HA1006
GroupedDBID 0R~
3V.
4.4
53G
5VS
7X7
88A
88E
88I
8FE
8FH
8FI
8FJ
AAFWJ
AAJSJ
AAKDD
ABDBF
ABUWG
ACGFS
ACSMW
ACUHS
ADBBV
ADRAZ
AENEX
AEUYN
AFKRA
AJTQC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
C6C
CCPQU
DIK
DWQXO
EBD
EBLON
EBS
ESX
FYUFA
GNUQQ
GROUPED_DOAJ
GX1
HCIFZ
HH5
HMCUK
HYE
KQ8
LK8
M0L
M1P
M2P
M48
M7P
M~E
NAO
OK1
PIMPY
PQQKQ
PROAC
PSQYO
RNT
RNTTT
RPM
SNYQT
UKHRP
AASML
AAYXX
AFPKN
CITATION
PHGZM
PHGZT
CGR
CUY
CVF
ECM
EIF
NPM
7XB
8FK
AARCD
COVID
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQUKI
PRINS
Q9U
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c455y-58d5412487cda19b5e04e709bc15df9fe1451eabc03fc67262530064366739303
IEDL.DBID M48
ISSN 2045-2322
IngestDate Wed Aug 27 01:28:54 EDT 2025
Thu Aug 21 18:25:01 EDT 2025
Mon Jul 21 11:28:15 EDT 2025
Wed Aug 13 11:25:26 EDT 2025
Thu Jan 02 22:45:18 EST 2025
Thu Apr 24 22:59:35 EDT 2025
Tue Jul 01 01:33:52 EDT 2025
Fri Feb 21 02:39:34 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License 2021. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c455y-58d5412487cda19b5e04e709bc15df9fe1451eabc03fc67262530064366739303
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1038/s41598-021-01930-y
PMID 34819514
PQID 2601731264
PQPubID 2041939
PageCount 10
ParticipantIDs doaj_primary_oai_doaj_org_article_afc0cc4016284319811206f3cc4de9a3
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8613264
proquest_miscellaneous_2602640123
proquest_journals_2601731264
pubmed_primary_34819514
crossref_primary_10_1038_s41598_021_01930_y
crossref_citationtrail_10_1038_s41598_021_01930_y
springer_journals_10_1038_s41598_021_01930_y
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20211124
PublicationDateYYYYMMDD 2021-11-24
PublicationDate_xml – month: 11
  year: 2021
  text: 20211124
  day: 24
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Scientific reports
PublicationTitleAbbrev Sci Rep
PublicationTitleAlternate Sci Rep
PublicationYear 2021
Publisher Nature Publishing Group UK
Nature Publishing Group
Nature Portfolio
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
– name: Nature Portfolio
References Novavax. Novavax COVID-19 vaccine demonstrates 89.3% efficacy in UK phase 3 Trial. https://www.globenewswire.com/news-release/2021/01/28/2166253/0/en/Novavax-COVID-19-Vaccine-Demonstrates-89-3-Efficacy-in-UK-Phase-3-Trial.html (2021).
VoyseyMSafety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKLancet2021397991111:CAS:528:DC%2BB3cXisFCgt77I10.1016/S0140-6736(20)32661-1333069897723445
WallECNeutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccinationLancet2021397233123331:CAS:528:DC%2BB3MXht12jtrvL10.1016/S0140-6736(21)01290-3340906248175044
ChenNEpidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive studyLancet20203955075131:CAS:528:DC%2BB3cXhvFOmsb8%3D10.1016/S0140-6736(20)30211-7320071437135076
WilliamsonEJFactors associated with COVID-19-related death using OpenSAFELYNature20205844304361:CAS:528:DC%2BB3cXhsFegtbzK10.1038/s41586-020-2521-4326404637611074
ImaiMSyrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure developmentProc. Natl. Acad. Sci. U S A202011716587165951:CAS:528:DC%2BB3cXhsFahtrvI10.1073/pnas.2009799117325719347368255
MaedaKNeutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasmaSci. Rep.20211155632021NatSR..11.5563M1:CAS:528:DC%2BB3MXmsVClsb4%3D10.1038/s41598-021-84733-5336924577946899
CeleSEscape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasmaNature20215931421462021Natur.593..142C1:CAS:528:DC%2BB3MXptlOntrs%3D10.1038/s41586-021-03471-w33780970
MelzackRThe short-form McGill Pain QuestionnairePain19873019119710.1016/0304-3959(87)91074-83670870
PlanasDReduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralizationNature20215962762802021Natur.596..276P1:CAS:528:DC%2BB3MXhslWnu7fO10.1038/s41586-021-03777-934237773
WadaYFor health care by taking the body temperatureJpn. Soc. Mech. Eng.2009112484485
WalshEESafety and immunogenicity of two RNA-based Covid-19 vaccine candidatesN. Engl. J. Med.2020383243924501:CAS:528:DC%2BB3cXis1yksLrM10.1056/NEJMoa202790633053279
HeathPTSafety and efficacy of NVX-CoV2373 Covid-19 vaccineN. Engl. J. Med.2021385117211831:CAS:528:DC%2BB3MXitV2ksbfO10.1056/NEJMoa210765934192426
Doria-RoseNAntibody persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-19N. Engl. J. Med.20213842259226110.1056/NEJMc2103916338224948524784
SadoffJSafety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19N. Engl. J. Med.2021384218722011:CAS:528:DC%2BB3MXhtlCrt7%2FE10.1056/NEJMoa210154433882225
XieXNeutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited seraNat. Med.2021276206211:CAS:528:DC%2BB3MXjsFGqsrs%3D10.1038/s41591-021-01270-433558724
OberhardtVRapid and stable mobilization of CD8(+) T cells by SARS-CoV-2 mRNA vaccineNature20215972682732021Natur.597..268O1:CAS:528:DC%2BB3MXhvVygtLrK10.1038/s41586-021-03841-4343206098426185
NodaKA novel highly quantitative and reproducible assay for the detection of anti-SARS-CoV-2 IgG and IgM antibodiesSci. Rep.20211151982021NatSR..11.5198N1:CAS:528:DC%2BB3MXlvF2gs78%3D10.1038/s41598-021-84387-3336642947933429
ZhouPA pneumonia outbreak associated with a new coronavirus of probable bat originNature20205792702732020Natur.579..270Z1:CAS:528:DC%2BB3cXksFKlsLg%3D10.1038/s41586-020-2012-7320155077095418
TurnerJSSARS-CoV-2 mRNA vaccines induce persistent human germinal centre responsesNature20215961091132021Natur.596..109T1:CAS:528:DC%2BB3MXhsFGqtr%2FN10.1038/s41586-021-03738-2341825698935394
MitsuyaHKokudoNSustaining containment of COVID-19: Global sharing for pandemic responseGlob. Health Med.20202535510.35772/ghm.2020.01040333307767731181
Pfizer. News/Pfizer and BioNTech conclude phase 3 study of COVID-19 vaccine candidate, meeting all primary efficacy endpoints. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine (2021).
RichmanDDCOVID-19 vaccines: Implementation, limitations and opportunitiesGlob. Health Med.202131510.35772/ghm.2021.01010336885887936373
ShindeVEfficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variantN. Engl. J. Med.2021384189919091:CAS:528:DC%2BB3MXhtFGju73I10.1056/NEJMoa2103055339513748091623
MatsuyamaSEnhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cellsProc. Natl. Acad. Sci. U S A2020117700170031:CAS:528:DC%2BB3cXmt1Gju7w%3D10.1073/pnas.2002589117321655417132130
VoyseyMSingle-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: A pooled analysis of four randomised trialsLancet20213978818911:CAS:528:DC%2BB3MXltFSnu7Y%3D10.1016/S0140-6736(21)00432-3336177777894131
Khoury, D., et al. What level of neutralising antibody protects from COVID-19? medRxiv (2021).
Earle, K. A., et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. medRxiv (2021).
Dal-ReROngoing and future COVID-19 vaccine clinical trials: Challenges and opportunitiesLancet Infect. Dis.202121e342e3471:CAS:528:DC%2BB3MXhtFGms7rP10.1016/S1473-3099(21)00263-2340198018131060
HattoriSIGRL-0920, an indole chloropyridinyl ester, completely blocks SARS-CoV-2 infectionMBio202010.1128/mBio.01833-20328200057441487
CohenJEffective vaccine offers shot of hope for pandemicScience20203707487492020Sci...370..748C1:CAS:528:DC%2BB3cXitlCmt7rK10.1126/science.370.6518.74833184184
YangXClinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational studyLancet Respir. Med.202084754811:CAS:528:DC%2BB3cXjvVWqt70%3D10.1016/S2213-2600(20)30079-5321056327102538
BadenLREfficacy and safety of the mRNA-1273 SARS-CoV-2 vaccineN. Engl. J. Med.20213844034161:CAS:528:DC%2BB3MXjvFSmsrc%3D10.1056/NEJMoa203538933378609
Johnson & Johnson. Johnson & Johnson COVID-19 vaccine authorized by U.S. FDA for emergency use—First single-shot vaccine in fight against global pandemic. https://www.jnj.com/johnson-johnson-covid-19-vaccine-authorized-by-u-s-fda-for-emergency-usefirst-single-shot-vaccine-in-fight-against-global-pandemic (2021).
WuFA new coronavirus associated with human respiratory disease in ChinaNature20205792652692020Natur.579..265W1:CAS:528:DC%2BB3cXksFKlsLc%3D32015508709494310.1038/s41586-020-2008-3
PolackFPSafety and efficacy of the BNT162b2 mRNA Covid-19 vaccineN. Engl. J. Med.2020383260326151:CAS:528:DC%2BB3MXotFSjuw%3D%3D10.1056/NEJMoa203457733301246
KorberBTracking changes in SARS-CoV-2 spike: Evidence that D614G increases infectivity of the COVID-19 virusCell20201828128271:CAS:528:DC%2BB3cXhsVCltL3I10.1016/j.cell.2020.06.043326979687332439
StephensDSMcElrathMJCOVID-19 and the path to immunityJAMA2020324127912811:CAS:528:DC%2BB3cXitVChsbfE10.1001/jama.2020.1665632915201
World Health Organization. Coronavirus disease (COVID-19) outbreak situation. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---29-june-2021 (2021).
TartofSYEffectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: A retrospective cohort studyLancet2021398140714161:CAS:528:DC%2BB3MXit1Whs7%2FF10.1016/S0140-6736(21)02183-8346190988489881
Takamatsu, Y., et al. Highly-neutralizing COVID-19-convalescent-plasmas potently block SARS-CoV-2 replication and pneumonia in Syrian hamsters. bioRxiv (2021).
WaldmannTAStroberWMetabolism of immunoglobulinsProg Allergy19691311101:CAS:528:DyaF1MXlt1WlurY%3D4186070
CollazosJAsensiVCartonJASex differences in the clinical, immunological and virological parameters of HIV-infected patients treated with HAARTAIDS20072183584310.1097/QAD.0b013e3280b0774a17415038
DS Stephens (1930_CR27) 2020; 324
1930_CR9
M Voysey (1930_CR36) 2021; 397
TA Waldmann (1930_CR25) 1969; 13
Y Wada (1930_CR42) 2009; 112
K Noda (1930_CR22) 2021; 11
J Collazos (1930_CR35) 2007; 21
M Imai (1930_CR39) 2020; 117
1930_CR19
X Yang (1930_CR33) 2020; 8
SY Tartof (1930_CR29) 2021; 398
LR Baden (1930_CR10) 2021; 384
1930_CR37
F Wu (1930_CR2) 2020; 579
FP Polack (1930_CR11) 2020; 383
1930_CR38
1930_CR13
J Sadoff (1930_CR14) 2021; 384
JS Turner (1930_CR26) 2021; 596
1930_CR1
P Zhou (1930_CR3) 2020; 579
DD Richman (1930_CR7) 2021; 3
N Chen (1930_CR32) 2020; 395
X Xie (1930_CR16) 2021; 27
V Shinde (1930_CR20) 2021; 384
D Planas (1930_CR30) 2021; 596
EC Wall (1930_CR21) 2021; 397
N Doria-Rose (1930_CR28) 2021; 384
J Cohen (1930_CR6) 2020; 370
PT Heath (1930_CR18) 2021; 385
R Melzack (1930_CR23) 1987; 30
H Mitsuya (1930_CR4) 2020; 2
R Dal-Re (1930_CR5) 2021; 21
SI Hattori (1930_CR41) 2020
M Voysey (1930_CR12) 2021; 397
V Oberhardt (1930_CR31) 2021; 597
1930_CR43
S Cele (1930_CR17) 2021; 593
EJ Williamson (1930_CR34) 2020; 584
EE Walsh (1930_CR8) 2020; 383
B Korber (1930_CR15) 2020; 182
S Matsuyama (1930_CR24) 2020; 117
K Maeda (1930_CR40) 2021; 11
34373860 - medRxiv. 2021 Jul 30
References_xml – reference: MatsuyamaSEnhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cellsProc. Natl. Acad. Sci. U S A2020117700170031:CAS:528:DC%2BB3cXmt1Gju7w%3D10.1073/pnas.2002589117321655417132130
– reference: World Health Organization. Coronavirus disease (COVID-19) outbreak situation. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---29-june-2021 (2021).
– reference: PolackFPSafety and efficacy of the BNT162b2 mRNA Covid-19 vaccineN. Engl. J. Med.2020383260326151:CAS:528:DC%2BB3MXotFSjuw%3D%3D10.1056/NEJMoa203457733301246
– reference: HattoriSIGRL-0920, an indole chloropyridinyl ester, completely blocks SARS-CoV-2 infectionMBio202010.1128/mBio.01833-20328200057441487
– reference: WalshEESafety and immunogenicity of two RNA-based Covid-19 vaccine candidatesN. Engl. J. Med.2020383243924501:CAS:528:DC%2BB3cXis1yksLrM10.1056/NEJMoa202790633053279
– reference: RichmanDDCOVID-19 vaccines: Implementation, limitations and opportunitiesGlob. Health Med.202131510.35772/ghm.2021.01010336885887936373
– reference: ShindeVEfficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variantN. Engl. J. Med.2021384189919091:CAS:528:DC%2BB3MXhtFGju73I10.1056/NEJMoa2103055339513748091623
– reference: OberhardtVRapid and stable mobilization of CD8(+) T cells by SARS-CoV-2 mRNA vaccineNature20215972682732021Natur.597..268O1:CAS:528:DC%2BB3MXhvVygtLrK10.1038/s41586-021-03841-4343206098426185
– reference: KorberBTracking changes in SARS-CoV-2 spike: Evidence that D614G increases infectivity of the COVID-19 virusCell20201828128271:CAS:528:DC%2BB3cXhsVCltL3I10.1016/j.cell.2020.06.043326979687332439
– reference: BadenLREfficacy and safety of the mRNA-1273 SARS-CoV-2 vaccineN. Engl. J. Med.20213844034161:CAS:528:DC%2BB3MXjvFSmsrc%3D10.1056/NEJMoa203538933378609
– reference: WilliamsonEJFactors associated with COVID-19-related death using OpenSAFELYNature20205844304361:CAS:528:DC%2BB3cXhsFegtbzK10.1038/s41586-020-2521-4326404637611074
– reference: Khoury, D., et al. What level of neutralising antibody protects from COVID-19? medRxiv (2021).
– reference: WallECNeutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccinationLancet2021397233123331:CAS:528:DC%2BB3MXht12jtrvL10.1016/S0140-6736(21)01290-3340906248175044
– reference: Johnson & Johnson. Johnson & Johnson COVID-19 vaccine authorized by U.S. FDA for emergency use—First single-shot vaccine in fight against global pandemic. https://www.jnj.com/johnson-johnson-covid-19-vaccine-authorized-by-u-s-fda-for-emergency-usefirst-single-shot-vaccine-in-fight-against-global-pandemic (2021).
– reference: Dal-ReROngoing and future COVID-19 vaccine clinical trials: Challenges and opportunitiesLancet Infect. Dis.202121e342e3471:CAS:528:DC%2BB3MXhtFGms7rP10.1016/S1473-3099(21)00263-2340198018131060
– reference: WadaYFor health care by taking the body temperatureJpn. Soc. Mech. Eng.2009112484485
– reference: NodaKA novel highly quantitative and reproducible assay for the detection of anti-SARS-CoV-2 IgG and IgM antibodiesSci. Rep.20211151982021NatSR..11.5198N1:CAS:528:DC%2BB3MXlvF2gs78%3D10.1038/s41598-021-84387-3336642947933429
– reference: WuFA new coronavirus associated with human respiratory disease in ChinaNature20205792652692020Natur.579..265W1:CAS:528:DC%2BB3cXksFKlsLc%3D32015508709494310.1038/s41586-020-2008-3
– reference: SadoffJSafety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19N. Engl. J. Med.2021384218722011:CAS:528:DC%2BB3MXhtlCrt7%2FE10.1056/NEJMoa210154433882225
– reference: StephensDSMcElrathMJCOVID-19 and the path to immunityJAMA2020324127912811:CAS:528:DC%2BB3cXitVChsbfE10.1001/jama.2020.1665632915201
– reference: ImaiMSyrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure developmentProc. Natl. Acad. Sci. U S A202011716587165951:CAS:528:DC%2BB3cXhsFahtrvI10.1073/pnas.2009799117325719347368255
– reference: MitsuyaHKokudoNSustaining containment of COVID-19: Global sharing for pandemic responseGlob. Health Med.20202535510.35772/ghm.2020.01040333307767731181
– reference: MelzackRThe short-form McGill Pain QuestionnairePain19873019119710.1016/0304-3959(87)91074-83670870
– reference: WaldmannTAStroberWMetabolism of immunoglobulinsProg Allergy19691311101:CAS:528:DyaF1MXlt1WlurY%3D4186070
– reference: Takamatsu, Y., et al. Highly-neutralizing COVID-19-convalescent-plasmas potently block SARS-CoV-2 replication and pneumonia in Syrian hamsters. bioRxiv (2021).
– reference: VoyseyMSafety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKLancet2021397991111:CAS:528:DC%2BB3cXisFCgt77I10.1016/S0140-6736(20)32661-1333069897723445
– reference: VoyseyMSingle-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: A pooled analysis of four randomised trialsLancet20213978818911:CAS:528:DC%2BB3MXltFSnu7Y%3D10.1016/S0140-6736(21)00432-3336177777894131
– reference: Novavax. Novavax COVID-19 vaccine demonstrates 89.3% efficacy in UK phase 3 Trial. https://www.globenewswire.com/news-release/2021/01/28/2166253/0/en/Novavax-COVID-19-Vaccine-Demonstrates-89-3-Efficacy-in-UK-Phase-3-Trial.html (2021).
– reference: TurnerJSSARS-CoV-2 mRNA vaccines induce persistent human germinal centre responsesNature20215961091132021Natur.596..109T1:CAS:528:DC%2BB3MXhsFGqtr%2FN10.1038/s41586-021-03738-2341825698935394
– reference: Doria-RoseNAntibody persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-19N. Engl. J. Med.20213842259226110.1056/NEJMc2103916338224948524784
– reference: TartofSYEffectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: A retrospective cohort studyLancet2021398140714161:CAS:528:DC%2BB3MXit1Whs7%2FF10.1016/S0140-6736(21)02183-8346190988489881
– reference: CeleSEscape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasmaNature20215931421462021Natur.593..142C1:CAS:528:DC%2BB3MXptlOntrs%3D10.1038/s41586-021-03471-w33780970
– reference: MaedaKNeutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasmaSci. Rep.20211155632021NatSR..11.5563M1:CAS:528:DC%2BB3MXmsVClsb4%3D10.1038/s41598-021-84733-5336924577946899
– reference: HeathPTSafety and efficacy of NVX-CoV2373 Covid-19 vaccineN. Engl. J. Med.2021385117211831:CAS:528:DC%2BB3MXitV2ksbfO10.1056/NEJMoa210765934192426
– reference: Pfizer. News/Pfizer and BioNTech conclude phase 3 study of COVID-19 vaccine candidate, meeting all primary efficacy endpoints. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine (2021).
– reference: Earle, K. A., et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. medRxiv (2021).
– reference: PlanasDReduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralizationNature20215962762802021Natur.596..276P1:CAS:528:DC%2BB3MXhslWnu7fO10.1038/s41586-021-03777-934237773
– reference: CohenJEffective vaccine offers shot of hope for pandemicScience20203707487492020Sci...370..748C1:CAS:528:DC%2BB3cXitlCmt7rK10.1126/science.370.6518.74833184184
– reference: CollazosJAsensiVCartonJASex differences in the clinical, immunological and virological parameters of HIV-infected patients treated with HAARTAIDS20072183584310.1097/QAD.0b013e3280b0774a17415038
– reference: YangXClinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational studyLancet Respir. Med.202084754811:CAS:528:DC%2BB3cXjvVWqt70%3D10.1016/S2213-2600(20)30079-5321056327102538
– reference: ZhouPA pneumonia outbreak associated with a new coronavirus of probable bat originNature20205792702732020Natur.579..270Z1:CAS:528:DC%2BB3cXksFKlsLg%3D10.1038/s41586-020-2012-7320155077095418
– reference: XieXNeutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited seraNat. Med.2021276206211:CAS:528:DC%2BB3MXjsFGqsrs%3D10.1038/s41591-021-01270-433558724
– reference: ChenNEpidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive studyLancet20203955075131:CAS:528:DC%2BB3cXhvFOmsb8%3D10.1016/S0140-6736(20)30211-7320071437135076
– volume: 397
  start-page: 881
  year: 2021
  ident: 1930_CR36
  publication-title: Lancet
  doi: 10.1016/S0140-6736(21)00432-3
– volume: 397
  start-page: 99
  year: 2021
  ident: 1930_CR12
  publication-title: Lancet
  doi: 10.1016/S0140-6736(20)32661-1
– volume: 21
  start-page: 835
  year: 2007
  ident: 1930_CR35
  publication-title: AIDS
  doi: 10.1097/QAD.0b013e3280b0774a
– volume: 383
  start-page: 2439
  year: 2020
  ident: 1930_CR8
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2027906
– volume: 21
  start-page: e342
  year: 2021
  ident: 1930_CR5
  publication-title: Lancet Infect. Dis.
  doi: 10.1016/S1473-3099(21)00263-2
– volume: 324
  start-page: 1279
  year: 2020
  ident: 1930_CR27
  publication-title: JAMA
  doi: 10.1001/jama.2020.16656
– volume: 384
  start-page: 403
  year: 2021
  ident: 1930_CR10
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2035389
– volume: 596
  start-page: 109
  year: 2021
  ident: 1930_CR26
  publication-title: Nature
  doi: 10.1038/s41586-021-03738-2
– volume: 383
  start-page: 2603
  year: 2020
  ident: 1930_CR11
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2034577
– volume: 8
  start-page: 475
  year: 2020
  ident: 1930_CR33
  publication-title: Lancet Respir. Med.
  doi: 10.1016/S2213-2600(20)30079-5
– volume: 596
  start-page: 276
  year: 2021
  ident: 1930_CR30
  publication-title: Nature
  doi: 10.1038/s41586-021-03777-9
– ident: 1930_CR9
– volume: 593
  start-page: 142
  year: 2021
  ident: 1930_CR17
  publication-title: Nature
  doi: 10.1038/s41586-021-03471-w
– volume: 384
  start-page: 2259
  year: 2021
  ident: 1930_CR28
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMc2103916
– ident: 1930_CR1
– volume: 182
  start-page: 812
  year: 2020
  ident: 1930_CR15
  publication-title: Cell
  doi: 10.1016/j.cell.2020.06.043
– volume: 579
  start-page: 265
  year: 2020
  ident: 1930_CR2
  publication-title: Nature
  doi: 10.1038/s41586-020-2008-3
– volume: 112
  start-page: 484
  year: 2009
  ident: 1930_CR42
  publication-title: Jpn. Soc. Mech. Eng.
– volume: 384
  start-page: 2187
  year: 2021
  ident: 1930_CR14
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2101544
– volume: 395
  start-page: 507
  year: 2020
  ident: 1930_CR32
  publication-title: Lancet
  doi: 10.1016/S0140-6736(20)30211-7
– volume: 384
  start-page: 1899
  year: 2021
  ident: 1930_CR20
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2103055
– volume: 11
  start-page: 5563
  year: 2021
  ident: 1930_CR40
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-021-84733-5
– volume: 30
  start-page: 191
  year: 1987
  ident: 1930_CR23
  publication-title: Pain
  doi: 10.1016/0304-3959(87)91074-8
– volume: 13
  start-page: 1
  year: 1969
  ident: 1930_CR25
  publication-title: Prog Allergy
– volume: 385
  start-page: 1172
  year: 2021
  ident: 1930_CR18
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2107659
– volume: 117
  start-page: 7001
  year: 2020
  ident: 1930_CR24
  publication-title: Proc. Natl. Acad. Sci. U S A
  doi: 10.1073/pnas.2002589117
– volume: 584
  start-page: 430
  year: 2020
  ident: 1930_CR34
  publication-title: Nature
  doi: 10.1038/s41586-020-2521-4
– ident: 1930_CR38
  doi: 10.1101/2021.03.17.20200246
– volume: 117
  start-page: 16587
  year: 2020
  ident: 1930_CR39
  publication-title: Proc. Natl. Acad. Sci. U S A
  doi: 10.1073/pnas.2018975117
– volume: 3
  start-page: 1
  year: 2021
  ident: 1930_CR7
  publication-title: Glob. Health Med.
  doi: 10.35772/ghm.2021.01010
– volume: 11
  start-page: 5198
  year: 2021
  ident: 1930_CR22
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-021-84387-3
– volume: 597
  start-page: 268
  year: 2021
  ident: 1930_CR31
  publication-title: Nature
  doi: 10.1038/s41586-021-03841-4
– ident: 1930_CR37
  doi: 10.1101/2021.03.09.21252641
– volume: 2
  start-page: 53
  year: 2020
  ident: 1930_CR4
  publication-title: Glob. Health Med.
  doi: 10.35772/ghm.2020.01040
– volume: 370
  start-page: 748
  year: 2020
  ident: 1930_CR6
  publication-title: Science
  doi: 10.1126/science.370.6518.748
– volume: 397
  start-page: 2331
  year: 2021
  ident: 1930_CR21
  publication-title: Lancet
  doi: 10.1016/S0140-6736(21)01290-3
– volume: 27
  start-page: 620
  year: 2021
  ident: 1930_CR16
  publication-title: Nat. Med.
  doi: 10.1038/s41591-021-01270-4
– ident: 1930_CR19
– ident: 1930_CR43
  doi: 10.1101/2021.06.29.450453
– volume: 579
  start-page: 270
  year: 2020
  ident: 1930_CR3
  publication-title: Nature
  doi: 10.1038/s41586-020-2012-7
– ident: 1930_CR13
– year: 2020
  ident: 1930_CR41
  publication-title: MBio
  doi: 10.1128/mBio.01833-20
– volume: 398
  start-page: 1407
  year: 2021
  ident: 1930_CR29
  publication-title: Lancet
  doi: 10.1016/S0140-6736(21)02183-8
– reference: 34373860 - medRxiv. 2021 Jul 30;:
SSID ssj0000529419
Score 2.5336394
Snippet While mRNA vaccines against SARS-CoV-2 are exceedingly effective in preventing symptomatic infection, their immune response features remain to be clarified. In...
Abstract While mRNA vaccines against SARS-CoV-2 are exceedingly effective in preventing symptomatic infection, their immune response features remain to be...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 22848
SubjectTerms 631/250/255/2514
631/326/590/2293
631/326/596/4130
Adult
Aged
Antibodies, Neutralizing - blood
Antibodies, Neutralizing - immunology
Antibodies, Neutralizing - pharmacology
Antibodies, Viral - blood
Antibodies, Viral - immunology
Antibody response
BNT162 Vaccine - adverse effects
BNT162 Vaccine - pharmacokinetics
COVID-19
COVID-19 - blood
COVID-19 - immunology
COVID-19 Vaccines - adverse effects
COVID-19 Vaccines - pharmacokinetics
Drug-Related Side Effects and Adverse Reactions
Female
Humanities and Social Sciences
Humans
Immune response
Immunogenicity, Vaccine - immunology
Immunoglobulin G
Immunologic Tests
Japan
Kinetics
Male
Middle Aged
mRNA
multidisciplinary
Neutralization
Prospective Studies
SARS-CoV-2 - genetics
SARS-CoV-2 - immunology
SARS-CoV-2 - pathogenicity
Science
Science (multidisciplinary)
Severe acute respiratory syndrome coronavirus 2
Side effects
Vaccines
Virions
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQJSQuiDeBgozEDax17Di2j-2KqkKiB7ZFvVmO44iIKkHdLlL4EfxmZpxs6PK8cEzsJNbMOPON7fmGkJdaSlkoWbLoOWeF8iXzWuZMSfRf3INTxfWOdyfl8Vnx9lydXyv1hWfCRnrgUXAL3wQeAkQBJfxIwV4MAAReNhLu1dH6xPMJPu9aMDWyegtb5HbKkuHSLNbgqTCbTGD0bCVnw44nSoT9v0OZvx6W_GnHNDmiozvk9oQg6cE48rvkRuzukZtjTcnhPvm2xHobFwghad_QLm7SWsZXeNdidfB-xZb9BybYKseYGB0XBdm2VV8P9HI8LxspLs5Sj6Wa4WI68QHdatpiNkmknwCaIr0zbTt6eHIKQqsE--JDaDv4LnSbs7zWD8jZ0ZvT5TGbii6wUCg1MGVqhRWpjQ61z22lIi-i5rYKuaob20Qs7Rt9FbhsQqkFxE8y4RqsHwpylQ_JXtd38TGhtbCVBxOJOvpC68qYyKsiWBOsDaIxGcm3CnBhYiTHwhgXLu2MS-NGpTlQmktKc0NGXs3PfB75OP7a-xD1OvdELu10AyzMTRbm_mVhGdnfWoWbJvjaIRMb2DTAyYy8mJthauJ-i-9iv0l9oB1Ba0YejUY0jwTznwHcwtN6x7x2hrrb0rUfE_23AQSWvvt6a4g_hvVnUTz5H6J4Sm4JnEF5zkSxT_auLjfxGYCyq-p5mn_fAZ-KMO4
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagCIkL4k2gICNxA2udOI7tE2pXVBUSPbAt2lvkOA5EVEnZ7SKFH8FvZsbxploePSaeJI5n7Pk845kh5LUSQuRSFMxbzlkubcGsEimTAvUXt6BU0d7x8aQ4Pss_LOUyGtzW8Vjldk0MC3XdO7SRzzD1FbwE9Pe7i-8Mq0ahdzWW0LhJbmHqMpRqtVSTjQW9WHlqYqwMF3q2Bn2FMWUZ7qGN4GzY0Uchbf-_sObfRyb_8JsGdXR0j9yNOJIejIy_T2747gG5PVaWHB6SX3OsunGOQJL2De38Jlg0fsK7ZouDTws27z-zjC1S3Bmj-qIwwm3V1wNdjadmPUUTLbVYsBku4rkPIKtpizElnn4DgIpJnmnb0cOT07TIqoz9sM61HXwXyKZYr_Ujcnb0_nR-zGLpBeZyKQcmdS2xLrVWrrapqaTnuVfcVC6VdWMajwV-va0cF40rVAa7KBHQDVYRhXEVj8le13f-KaF1ZioLguKVt7lSldaeV7kz2hnjskYnJN0yoHQxLzmWxzgvg39c6HJkWglMKwPTyiEhb6ZnLsasHNdSHyJfJ0rMqB1u9KsvZZygpW0cdw52mwUobFiXNABRXjQC7tXeWJGQ_a1UlHGar8sroUzIq6kZJih6XWzn-02ggXaErgl5MgrR1BOMggaIC0-rHfHa6epuS9d-DUnANeCw8N23W0G86tb_h-LZ9X_xnNzJcG6kKcvyfbJ3udr4FwC6LquXYWb9Bnz0KMg
  priority: 102
  providerName: ProQuest
– databaseName: Springer Nature HAS Fully OA
  dbid: AAJSJ
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Nb9QwELVKKyQuiG8CBRmJG1h17Dixj9sVVbUSPbAt6s1yHAciqgTtdpHCj-A3M-NkgxYKEseNx1nLM8482zNvCHldSCkzJXMWHOcsUy5nrpApUxL9F3fgVPG84_1ZfnqRLS7V5R4R21yYGLQfKS3jZ3obHXa0BkeDyWACN79GctbfIgdI1Q62fTCbLZaL6WQF766y1IwZMlzqGzrveKFI1n8TwvwzUPK329LohE7ukbsjeqSzYbz3yV5oH5DbQz3J_iH5McdaG1cIH2lX0zZs4jnGd3jX0XL2Ycnm3Ucm2DLF_TA6LQrz2pRd1dPVECsbKB7MUodlmuHHGO0BYhVtMJMk0C8AS5HamTYtPT47T3NRCvbNed_AhAYQmzK81o_Ixcm78_kpGwsuMJ8p1TOlK4XVqHXhK5eaUgWehYKb0qeqqk0dsKxvcKXnsvZ5IWDvJCOmwdqhMK_yMdlvuzY8JbQSpnRgHqEILiuKUuvAy8wb7Y3xotYJSbcKsH5kI8eiGFc23opLbQelWVCajUqzfULeTH2-Dlwc_5Q-Rr1OksijHR90q092tCvras-9hz1mDm4avkYa4CfPawnPqmCcTMjh1irsuLjXFlnYwJ4BSibk1dQMyxLvWlwbuk2UgXYErAl5MhjRNBLMfQZgC72LHfPaGepuS9t8jtTfGtBX_N-3W0P8Nay_T8Wz_xN_Tu4IXCtpykR2SPavV5vwAqDXdflyXGs_AXZkKH8
  priority: 102
  providerName: Springer Nature
Title Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals
URI https://link.springer.com/article/10.1038/s41598-021-01930-y
https://www.ncbi.nlm.nih.gov/pubmed/34819514
https://www.proquest.com/docview/2601731264
https://www.proquest.com/docview/2602640123
https://pubmed.ncbi.nlm.nih.gov/PMC8613264
https://doaj.org/article/afc0cc4016284319811206f3cc4de9a3
Volume 11
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELb2ISQuiDeBpTISNzCbxEkcHxBqo12tKm2FtlvUW-Q4zhJRJbvtFhF-BL-ZGScpKhROnKr40Viemcznx8xHyGvBOQ9CHjGjXJcFoYqYEtxjIUf_5SpwqrjfcT6JzmbBeB7O90hPd9RN4Grn0g75pGbLxbtvN80HMPj3bch4fLwCJ4SBYj4ujCV3WbNPDsEzCWQ0OO_gfpvr25eBJ7vYmd1dt_yTTeO_C3v-eYXyt3NU655O75N7Ha6kw1YRHpA9Uz0kd1qmyeYR-ZEgC8cCgSWtC1qZtd3h-A7_dTwdXkxZUn9iPpt6uFJGd0Zhxsuszhu6bG_RGopbtlQhgTM8dPdAoFlOS4wxMfQLAFZM-kzLio4ml17kZz77qrQuK3gvNNvEfq0ek9npyWVyxjoqBqaDMGxYGOch8lTHQufKk1lo3MAIV2baC_NCFgYJf43KtMsLHQkfVlXcoh1kFYV55U_IQVVX5hmhuS8zBYpjhFGBEFkcGzcLtIy1lNovYod4vQBS3eUpR7qMRWrPy3mctkJLQWipFVraOOTNps91m6Xjn61HKNdNS8ywbQvq5VXaGWyqCu1qDavPCBw4fKdiAKZuVHAoy41U3CFHvVakvdammJ8NNB1ApkNebarBYPEURlWmXts2UI9Q1iFPWyXajASjogHyQm-xpV5bQ92uqcrPNil4DLjMvvdtr4i_hvX3qXj-P6biBbnrowV5HvODI3Jwu1yblwDVbrMB2RdzMSCHw-F4Oobf0cnk4wWUJlEysNsfA2uhPwFFQz7y
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LbxMxELZKEYIL4s1CASPBCax47X0eEGoDVUrbHEiKcjNerxciqt2SNKDlR_BT-I3MeB9VePTWY9aP9WbG8_B45iPkWSylDEIZMas5Z0GoI6Zj6bNQov7iGpQqnnccjqPRUfBuFs42yK8uFwavVXYy0QnqvDJ4Rj7A0lcwCejv1ydfGaJGYXS1g9Bo2GLf1t_BZVu-2nsD9H0uxO7b6XDEWlQBZoIwrFmY5CFCLiexybWfZqHlgY15mhk_zIu0sIhda3VmuCxMFAtwEKRT3AiQmYLEh3kvkcugeDk6e_Es7s90MGoW-Gmbm8NlMliCfsQcNoE-Owxm9Zr-czAB_7Jt_76i-Uec1qm_3Rvkemu30u2G0W6SDVveIlcaJMv6Nvk5RJSPYzRcaVXQ0q7cCcoPmGsw2X4_YcPqAxNs4qMnjuqSAkXnWZXXdNHc0rUUj4SpRoBo-NHeM4FuOZ1jDoulX8AgxqLSdF7SnfHUj0Qm2DdtzLyE90K3PrdseYccXQhR7pLNsirtfUJzkWYaGNPGVgdxnCWJ5Vlg0sSkqRFF4hG_I4AybR10hOM4Vi4eLxPVEE0B0ZQjmqo98qIfc9JUATm39w7Ste-JFbzdg2rxSbUCQenCcGPAu43AQAA5mIDhy6NCwrPcplp6ZKvjCtWKlaU62wQeedo3g0DAKI8ubbVyfaAdTWWP3GuYqF8JZl2DSQ2j4zX2Wlvqeks5_-yKjidg97n3vuwY8WxZ__8rHpz_FU_I1dH08EAd7I33H5JrAveJ7zMRbJHN08XKPgKD7zR77HYZJR8velv_BnfbY4s
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Zb9QwELbKViBeEDeBAkaCJ7A2sXM-INTddtVSWFXdFvXNOI4DEVVSdrug8CP4Qfw6ZpyjWo6-9XHjI87OeA6PZz5CnkdCCD8QITPKdZkfqJCpSHgsEKi_XAVKFc873k_DnSP_7XFwvEZ-dbkweK2yk4lWUGeVxjPyIZa-gklAfw_z9lrE_tbkzelXhghSGGnt4DQaFtkz9Xdw3xavd7eA1i84n2wfjndYizDAtB8ENQviLED45TjSmfKSNDCubyI3SbUXZHmSG8SxNSrVrsh1GHFwFoRV4giWmYD0h3mvkPUIvaIBWR9tT_cP-hMejKH5XtJm6rgiHi5AW2JGG0cPHoazekUbWtCAf1m6f1_Y_CNqa5Xh5Ca50VqxdLNhu1tkzZS3ydUG17K-Q36OEfPjBM1YWuW0NEt7nvID5hrONg9mbFx9YJzNPPTLUXlSoG-RVllN582dXUPxgJgqhIuGH-2tE-iW0QIzWgz9AuYxlpimRUlH00Mv5Cln35TWRQnvhW59ptniLjm6FLLcI4OyKs0DQjOepArY1ERG-VGUxrFxU18nsU4SzfPYIV5HAKnbqugIznEibXRexLIhmgSiSUs0WTvkZT_mtKkJcmHvEdK174n1vO2Dav5JtuJBqly7WoOvG4K5AFIxBjPYDXMBzzKTKOGQjY4rZCtkFvJ8SzjkWd8M4gFjPqo01dL2gXY0nB1yv2GifiWYgw0GNoyOVthrZamrLWXx2ZYgj8EKtO991THi-bL-_1c8vPgrnpJrsKXlu93p3iNyneM28TzG_Q0yOJsvzWOw_s7SJ-02o-TjZe_s31PQaSY
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Correlates+of+neutralizing%2FSARS-CoV-2-S1-binding+antibody+response+with+adverse+effects+and+immune+kinetics+in+BNT162b2-vaccinated+individuals&rft.jtitle=Scientific+reports&rft.au=Kenji+Maeda&rft.au=Masayuki+Amano&rft.au=Yukari+Uemura&rft.au=Kiyoto+Tsuchiya&rft.date=2021-11-24&rft.pub=Nature+Portfolio&rft.eissn=2045-2322&rft.volume=11&rft.issue=1&rft.spage=1&rft.epage=10&rft_id=info:doi/10.1038%2Fs41598-021-01930-y&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_afc0cc4016284319811206f3cc4de9a3
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon